Form 4: Cue Biopharma Executive Granted 200,000 Stock Options

Cue Biopharma's Chief Development Officer, Daniel G. Baker, was granted 200,000 stock options on November 25, 2024, exercisable over two years.

Summary

• Daniel G. Baker, Chief Development Officer of Cue Biopharma, Inc., was granted 200,000 stock options on November 25, 2024.
• The exercise price of these options is $1.06 per share.
• The options will vest in equal semi-annual installments over two years, starting on May 25, 2025.
• The options expire on November 24, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative news or concerns.

Positives

• The granting of stock options to a key executive like the Chief Development Officer can be seen as an incentive to align their interests with the company's long-term success.
• The vesting schedule encourages the executive's continued commitment to the company over the next two years.

Risks

• The value of the stock options is dependent on the future performance of Cue Biopharma's stock price.
• If the stock price does not increase above the exercise price of $1.06, the options may not be valuable to the executive.

Future Outlook

The stock options will vest over the next two years, incentivizing the executive to contribute to the company's growth and success.

Industry Context

Stock options are a common form of compensation for executives in the biotechnology industry, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Granting stock options to executives is a standard practice in the biotech industry, similar to companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedule of two years is also typical, aligning with industry norms for executive compensation packages.
• The exercise price of $1.06 is specific to Cue Biopharma's stock price at the time of the grant.

Stakeholder Impact

• Shareholders may view the granting of stock options positively as it incentivizes management to increase the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Cue Biopharma, equity, vesting